Cerebrolysin vs NSI-189
A side-by-side research comparison of Cerebrolysin and NSI-189 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | NSI-189 |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | NSI-189 Phosphate (Neurogenic Compound) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Investigational |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. |
| Molecular weight | <10,000 Da (peptide fraction) | 366.4 Da |
| Half-life | 4-6 hours | 18-22 hours |
| Bioavailability | High (IM/IV) | High (oral) |
| Typical dose | 5-30 mL | 40-80 mg |
| Frequency | Daily for 10-20 days | Once daily |
| Route | Intramuscular or IV | Oral |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
Related comparisons
Research and educational reference only. Not medical advice.